AI-Powered Stress Biomarkers Make their Way into Clinical Practice: Mobio Interactive and Divergence Neuro Announce Strategic Partnership

SINGAPORE and TORONTO – 2 March 2026 – Mobio Interactive, a leader in AI-native objective stress measurement, today announced a strategic integration with Divergence Neuro to embed real-time facial biomarker technology into clinical neuroadaptive workflows.

This partnership marks a shift from "guessing to knowing" in mental health. By integrating Mobio’s proprietary AI into the Divergence platform, clinicians can now see a patient’s physiological stress response in real-time, adding measurable data to complement subjective reporting.

The Science of Seeing Stress

Mobio’s technology utilizes advanced computer vision to analyze micro-expressions and facial blood flow patterns, generating validated stress biomarkers via a standard camera. Just like wearable sensors, just without the hardware, Mobio’s software-only solution provides:

• Real-Time Feedback: Instant visualization of stress spikes during clinical sessions.
• Longitudinal Tracking: Comparing physiological data across weeks of treatment to prove efficacy.
• Reduced Patient Burden: Eliminating "survey fatigue" by capturing data passively and accurately.

“The 'gold standard' in mental health no longer needs to be subjective,” said Bechara Saab, PhD, CEO and Chief Scientist of Mobio Interactive. “Our partnership with Divergence Neuro shows there is demand for unbiased tools, when easy for patients to use, and accessible to nearly anyone. We’re committed to advancing objective data as a framework for mental health.”

A Unified Vision for Neuroadaptive Care

The integration strengthens Divergence Neuro’s position as a comprehensive multimodal neuro platform.

“Integrating Mobio’s facial biomarkers allows our providers to observe stress responses more consistently, both during sessions and over the course of treatment”, said Alex Ni, CEO of Divergence Neuro. “By combining brainwave data with Mobio’s real-time stress insights, we are giving clinicians an unprecedented ability to tailor treatments to the individual in front of them.”

Clinical Impact and Global Reach

Mobio’s AI-powered stress biomarker technology has undergone clinical validation in diverse populations across skin tones with published studies demonstrating statistically significant and clinically meaningful effects. This partnership scales this validated technology to Divergence’s growing network of therapists, clinics, and research institutions worldwide.

Key Benefits for Clinicians:

1. Objective Assessments: Complementing patient-reported outcomes with hard physiological data.
2. Precision Personalization: Adjusting therapy protocols based on real-time stress triggers.
3. Enhanced Engagement: Using visualized data to help patients understand their own physiological responses.

About Mobio Interactive
Headquartered in Singapore, Mobio Interactive is an AI-native digital health company at the forefront of the objective mental health revolution. Its flagship technology provides real-time, clinically validated stress measurements through facial biomarkers, enabling personalized care at scale.
Website: www.mobiointeractive.com

About Divergence Neuro
Divergence Neuro is a cloud-based neuroadaptive platform that connects therapists and patients through data-driven mental health tools. By integrating EEG, AI, and digital biomarkers, Divergence is building the future of evidence-based neuro-care.
Website: www.divergenceneuro.com

Media Contact:
Sathya Krishnan
Chief Marketing Officer
sathya@mobiointeractive.com